Fabry Disease Clinical Trials

35 recruiting

Fabry Disease Trials at a Glance

38 actively recruiting trials for fabry disease are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Fairfax, Atlanta, and London. Lead sponsors running fabry disease studies include Chiesi Farmaceutici S.p.A., Amicus Therapeutics, and IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Browse fabry disease trials by phase

Treatments under study

About Fabry Disease Clinical Trials

Looking for clinical trials for Fabry Disease? There are currently 35 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Fabry Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Fabry Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 38 trials

Recruiting

Fabry Disease Registry & Pregnancy Sub-registry

Fabry Disease
Genzyme, a Sanofi Company9,000 enrolled283 locationsNCT00196742
Recruiting

A Study of Patients With Fabry Disease (US Specific)

Fabry Disease
Amicus Therapeutics450 enrolled8 locationsNCT06906367
Recruiting
Phase 3

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

Fabry Disease
Amicus Therapeutics8 enrolled11 locationsNCT06904261
Recruiting
Not Applicable

Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI

Fabry Disease
University Health Network, Toronto300 enrolled1 locationNCT04856059
Recruiting
Not Applicable

T1 Mapping in Fabry Disease

Fabry Disease
Hospices Civils de Lyon70 enrolled2 locationsNCT05923788
Recruiting

Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

PregnancyFabry DiseasePregnancy Complications
Chiesi Farmaceutici S.p.A.10 enrolled5 locationsNCT06941025
Recruiting
Phase 2Phase 3

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Fabry Disease
Chiesi Farmaceutici S.p.A.22 enrolled12 locationsNCT06328608
Recruiting
Phase 2Phase 3

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease

Fabry Disease
Chiesi Farmaceutici S.p.A.16 enrolled10 locationsNCT05710692
Recruiting
Not Applicable

Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease

Fabry Disease
The Children's Hospital of Zhejiang University School of Medicine12 enrolled2 locationsNCT06539624
Recruiting
Not Applicable

Long Duration Holter ECG in Fabry Disease

Fabry Disease
Institut National de la Santé Et de la Recherche Médicale, France40 enrolled1 locationNCT04440254
Recruiting

Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes

Anderson Fabry DiseaseAmyloid CardiomyopathyCardiac Magnetic Resonance Imaging+1 more
IRCCS Azienda Ospedaliero-Universitaria di Bologna250 enrolled1 locationNCT07382128
Recruiting

Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques

Noonan SyndromeFabry DiseaseCardiac Amyloidosis+4 more
Chinese Academy of Medical Sciences, Fuwai Hospital1,000 enrolled1 locationNCT07336394
Recruiting

Taiwan Associated Genetic and Nongenetic Small Vessel Disease

StrokeMagnetic Resonance ImagingFabry Disease+5 more
National Taiwan University Hospital500 enrolled1 locationNCT05473637
Recruiting

A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease

Fabry Disease
Takeda200 enrolled18 locationsNCT07187440
Recruiting

Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment

Fabry DiseaseAged 65 Years or OlderAlpha Galactosidase A Deficiency+1 more
Wladimir MAUHIN, Dr100 enrolled1 locationNCT07277361
Recruiting

Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study

Fabry Disease
Yonsei University25 enrolled1 locationNCT07235709
Recruiting

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Fabry Disease
Chiesi Farmaceutici S.p.A.100 enrolled10 locationsNCT06663358
Recruiting
Phase 1Phase 2

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

Fabry Disease
UniQure Biopharma B.V.12 enrolled8 locationsNCT06270316
Recruiting
Phase 4

A Study of Replagal in Children and Adults With Fabry Disease in India

Fabry Disease
Shire5 enrolled3 locationsNCT05067868
Recruiting

Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study

Fabry Disease
University of Minnesota50 enrolled2 locationsNCT01581424